90 found
Sort by:
Disambiguations:
Jeffrey P. Kahn [26]Jeffrey Kahn [16]Jonathan Kahn [10]Joel S. Kahn [9]
J. Kahn [7]Jean Kahn [4]Journet Kahn [4]Joan Yess Kahn [3]

Not all matches are shown. Search with initial or firstname to single out others.

  1. Joan Y. Kahn (forthcoming). Research Associate McGill University, Quality of Working Life Unit 1001 Sherbrooke St. West Montreal, Quebec Canada H3A 1G5. [REVIEW] Semiotics.
    No categories
     
    My bibliography  
     
    Export citation  
  2. Jonathan Kahn (forthcoming). Perspective:" Ethnic Drugs". Hastings Center Report.
     
    My bibliography  
     
    Export citation  
  3. John A. Robertson, Jeffrey P. Kahn & John E. Wagner (forthcoming). Conception. Hastings Center Report.
    Direct download  
     
    My bibliography  
     
    Export citation  
  4. E. Vayena, R. Brownsword, S. J. Edwards, B. Greshake, J. P. Kahn, N. Ladher, J. Montgomery, D. O'Connor, O. O'Neill, M. P. Richards, A. Rid, M. Sheehan, P. Wicks & J. Tasioulas (forthcoming). Research Led by Participants: A New Social Contract for a New Kind of Research. Journal of Medical Ethics.
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  5. Susan M. Wolf & Jeffrey P. Kahn (forthcoming). Bioethics Matures: The Field Faces the Future. Hastings Center Report.
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  6. Jonathan Kahn (2015). Review of Lundy Braun, Breathing Race Into the Machine: The Surprising Career of the Spirometer From Plantation to Genetics. [REVIEW] American Journal of Bioethics 15 (2):5-6.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  7. Jeffrey Kahn (2014). Lessons Learned: Challenges in Applying Current Constraints on Research on Chimpanzees to Other Animals. Theoretical Medicine and Bioethics 35 (2):97-104.
    The Institute of Medicine (IOM) Committee on the Necessity of the Use of Chimpanzees in Biomedical and Behavioral Research made a series of recommendations that, as of an announcement on June 26, 2013, the National Institutes of Health (NIH) is turning into implemented guidelines. Many advocates, including some researchers and scholars, have suggested that the Committee’s recommendations could be applied successfully to other animal species. This article examines, from my perspective as the IOM Committee’s chair, some of the most important (...)
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  8. Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine & Ethics 40 (4):716-750.
    The nanomedicine field is fast evolving toward complex, “active,” and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  9. Jeffrey Kahn (2012). Raising the Bar: The Implications of the IOM Report on the Use of Chimpanzees in Research. Hastings Center Report 42 (s1):S27 - S30.
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation  
  10. Jonathan Kahn (2012). The Troubling Persistence of Race in Pharmacogenomics. Journal of Law, Medicine & Ethics 40 (4):873-885.
    This article is concerned about what may be happening to race and medicine in the “meantime” between today's clinical realities and the promised land of pharmacogenomics where the need for using race in medicine is supposed to fade away. It argues that previous debates over the use of race in medicine are being side-stepped as race is being reconfigured from a “crude surrogate” for genetic variation into a purportedly viable placeholder for variable drug response — to be used here and (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  11. Jean-Paul Baldacchino & Joel S. Kahn, Believing in a Secular Age: Anthropology, Sociology and Religious Experience.
    Charles Taylor’s A Secular Age generated a great deal of attention—and has stimulated important debates—among a diverse range of scholars in sociology, history, politics, religious studies and to a lesser extent, anthropologists. Much of the debate has focused on the implications of Taylor’s work for the so-called secularisation thesis and the place (or non-place) of religion in the so-called public sphere. The essays in this volume arise less out of such concerns and more from Taylor’s discussion of secularism in a (...)
    Translate to English
    | Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  12. Jean-François Kahn (2011). Philosophie de la Réalité: Critique du Réalisme. Fayard.
    Translate to English
    |
     
    My bibliography  
     
    Export citation  
  13. Jonathan Kahn (2011). The Two (Institutional) Cultures A Consideration of Structural Barriers to Interdisciplinarity. Perspectives in Biology and Medicine 54 (3):399-408.
    The famous 1959 Two Cultures essay by C. P. Snow has become a foil for decades of discussions over the relation between science and the humanities. The problem of the “two cultures” is often framed in terms of how the particular epistemological claims or general intellectual orientations of particular individuals on either side of this purported divide obstruct interdisciplinary dialogue or cooperation. This formulation, however, is ultimately unsatisfying, because often it focuses narrowly on the intentions and arguments of individuals, without (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  14. P. S. Duggan, A. W. Siegel, D. M. Blass, H. Bok, J. T. Coyle, R. Faden, J. Finkel, J. D. Gearhart, H. T. Greely, A. Hillis, A. Hoke, R. Johnson, M. Johnston, J. Kahn, D. Kerr & P. King (2009). Unintended Changes in Cognition, Mood, and Behavior Arising From Cell-Based Interventions for Neurological Conditions: Ethical Challenges. American Journal of Bioethics 9 (5):31-36.
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  15. Jean Kahn (2009). A Propos d'Une Correction À Apporter du Texte d'Une Définition du Beau Dans la Critique de la Faculté de Juger. Kant-Studien 100 (1):106-106.
  16. Jeffrey P. Kahn (2009). Commentary: Who's Afraid of the RAC? Lessons From the Oversight of Controversial Science. Journal of Law, Medicine & Ethics 37 (4):685-687.
    This commentary asks what we can learn from our oversight of controversial science and how can we do better in the future? After briefly examining the history of gene transfer research oversight, some observations are offered for the oversight of nanobiotechnology and other emerging areas of science.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  17. Jeffrey Kahn & Anna Mastroianni (2009). The Implications of Public Health for Bioethics. In Bonnie Steinbock (ed.), The Oxford Handbook of Bioethics. OUP Oxford
     
    My bibliography  
     
    Export citation  
  18. Joel S. Kahn (2009). Minangkabau Social Formations: Indonesian Peasants and the World-Economy. Cambridge University Press.
    In this anthropological investigation of the nature of an underdeveloped peasant economy, Joel S. Kahn attempts to develop the insights generated by Marxist theorists, by means of a concrete case study of a peasant village in the Indonesian province of West Sumatra. He accounts for the specific features of this regional economy, and, at the same time, examines the implications for it of the centuries-old European domination of Indonesia. The most striking feature of the Minangkabau economy is the predominance of (...)
    No categories
     
    My bibliography  
     
    Export citation  
  19. George T. H. Ellison, Jay S. Kaufman, Rosemary F. Head, Paul A. Martin & Jonathan D. Kahn (2008). Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients. Journal of Law, Medicine & Ethics 36 (3):449-457.
    The U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil for heart failure specifically in black patients was based on under-powered, post hoc subgroup analyses of two relatively old trials , which were further complicated by substantial covariate imbalances between racial groups. Indeed, the only statistically significant difference observed between black and white patients was found without any adjustment for potential confounders in samples that were unlikely to have been adequately randomized. Meanwhile, because the accepted (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  20. Jeffrey Kahn (2008). An Unprotected Public. American Journal of Bioethics 8 (6):3 – 4.
    Direct download (5 more)  
     
    My bibliography  
     
    Export citation  
  21. Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian van Ness & Benjamin S. Wilfond (2008). Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations. Journal of Law, Medicine & Ethics 36 (2):219-248.
    No consensus yet exists on how to handle incidental fnd-ings in human subjects research. Yet empirical studies document IFs in a wide range of research studies, where IFs are fndings beyond the aims of the study that are of potential health or reproductive importance to the individual research participant. This paper reports recommendations of a two-year project group funded by NIH to study how to manage IFs in genetic and genomic research, as well as imaging research. We conclude that researchers (...)
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  22. Jeffrey Kahn (2007). What Vaccination Programs Mean for Research. American Journal of Bioethics 7 (3):3 – 4.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  23. Jeffrey P. Kahn (2007). Baseball, Alcohol and Public Health. American Journal of Bioethics 7 (7):3.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  24. Jeffrey P. Kahn (2007). Organs and Stem Cells: Policy Lessons and Cautionary Tales. Hastings Center Report 37 (2):11-12.
  25. Jeffrey P. Kahn (2007). Why Public Health and Politics Don't Mix. American Journal of Bioethics 7 (11):3 – 4.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  26. Jeffrey P. Kahn & Susan M. Wolf (2007). Understanding the Role of Genetics in Disability Insurance. Journal of Law, Medicine & Ethics 35 (s2):5-5.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  27. Susan M. Wolf & Jeffrey P. Kahn (2007). Genetic Testing and the Future of Disability Insurance: Ethics, Law & Policy. Journal of Law, Medicine & Ethics 35 (s2):6-32.
    Predictive genetic testing poses fundamental questions for disability insurance, a crucial resource funding basic needs when disability prevents income from work. This article, from an NIH-funded project, presents the first indepth analysis of the challenging issues: Should disability insurers be permitted to consider genetics and exclude predicted disability? May disabilities with a recognized genetic basis be excluded from coverage as pre-existing conditions? How can we assure that private insurers writing individual and group policies, employers, and public insurers deal competently and (...)
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  28. S. Farber, R. Costanza, D. L. Childers, J. Erickson, K. Gross, M. Grove, C. Hopkinson, J. Kahn, S. Pincetl & A. Troy (2006). Linking Ecology and Economics for Ecosystem Management. BioScience 56 (2):121-133.
    Direct download  
     
    My bibliography  
     
    Export citation  
  29. Stephen Farber, Robert Costanza, Daniel L. Childers, Jon Erickson, Katherine Gross, Morgan Grove, Charles S. Hopkinson, James Kahn, Stephanie Pincetl & Austin Troy (2006). Linking Ecology and Economics for Ecosystem Management. BioScience 56 (2):121-133.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  30. J. P. Kahn (2006). What Happens When Bioethics Discovers Politics. Hastings Center Report 36 (3):10.
     
    My bibliography  
     
    Export citation  
  31. Jeffrey P. Kahn (2006). What Happens When Politics Discovers Bioethics? Hastings Center Report 36 (3):10-10.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  32. Jonathan Kahn (2006). Race, Pharmacogenomics, and Marketing: Putting BiDil in Context. American Journal of Bioethics 6 (5):W1-W5.
    This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived (...)
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  33. Jeffrey P. Kahn (2005). Letter to the Editor. American Journal of Bioethics 5 (3):W13-W13.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  34. Joel S. Kahn (2005). Anthropology's Malaysian Interlocutors : Toward a Cosmopolitan Ethics of Anthropological Practice. In Lynn Meskell & Peter Pels (eds.), Embedding Ethics. Berg 101.
    Direct download  
     
    My bibliography  
     
    Export citation  
  35. Jonathan Kahn (2005). Ethnic Drugs. Hastings Center Report 35 (1).
    Direct download  
     
    My bibliography  
     
    Export citation  
  36. Jonathan Kahn (2005). "Ethnic Drugs&Quot. Hastings Center Report 35 (1):c3-c3.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  37. Susan M. Wolf & Jeffrey P. Kahn (2005). Bioethics Matures:. Hastings Center Report 35 (4):22-24.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  38. Stella Gonzalez Arnal, Donald Chalmers, David Kum-Wah Chan, Margaret Coffey, Jo Ann T. Croom, Mylène Deschênes, Henrich Ganthaler, Yuri Gariev, Ryuichi Ida, Jeffrey P. Kahn, Martin O. Makinde, Anna C. Mastroianni, Katharine R. Meacham, Bushra Mirza, Michael J. Morgan, Dianne Nicol, Edward Reichman, Susan E. Wallace & Larissa P. Zhiganova (2004). Cross-Cultural Biotechnology: A Reader. Rowman & Littlefield Publishers.
    This book is a rich blend of analyses by leading experts from various cultures and disciplines. A compact introduction to a complex field, it illustrates biotechnology's profound impact upon the environment and society. Moreover, it underscores the vital relevance of cultural values. This book empowers readers to more critically assess biotechnology's value and effectiveness within both specific cultural and global contexts.
     
    My bibliography  
     
    Export citation  
  39. Jeffrey Kahn (2004). Genetic Counselors' Impact on the Genetics Revolution: Recommendations of an Informed Outsider. Bioethics Examiner 8.
    Direct download  
     
    My bibliography  
     
    Export citation  
  40. Jeffrey P. Kahn & Anna C. Mastroianni (2004). Creating a Stem Cell Donor: A Case Study in Reproductive Genetics. Kennedy Institute of Ethics Journal 14 (1):81-96.
    : During the nearly 10 years since its introduction, preimplantation genetic diagnosis (PGD) has been used predominantly to avoid giving birth to a child with identified genetic disease. Recently, PGD was used by a couple not only to test IVF-created embryos for genetic disease, but also to test for a nondisease trait related to immune compatibility with a child in the family in need of an hematopoetic stem cell transplant. This article describes the case, raises some ethical and policy issues, (...)
    Direct download (6 more)  
     
    My bibliography  
     
    Export citation  
  41. Jeffrey Kahn & Anna Mastroianni (2004). Looking Forward in Bioethics. Journal of Law, Medicine & Ethics 32 (2):196-197.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  42. Jonathon S. Kahn (2004). Religion and the Binding of the Souls of Black Folk. Philosophia Africana 7 (2):17-31.
    Direct download  
     
    My bibliography  
     
    Export citation  
  43. Tom L. Beauchamp, Howard Brody, Franklin G. Miller, Alexander S. Curtis, Martina Darragh, Patricia Milmoe, Ronald M. U. S. Green, Sharona Hoffman, Edmund G. Howe & Jeffrey P. Kahn (2003). By Author BAGHERI, Alireza. Criticism of “Brain. Kennedy Institute of Ethics Journal 13 (4):407-09.
    No categories
    Direct download  
     
    My bibliography  
     
    Export citation  
  44. Jeffrey P. Kahn (2003). Three Views of Organ Procurement Policy: Moving Ahead or Giving Up? Kennedy Institute of Ethics Journal 13 (1):45-50.
    : The supply of organs for transplant remains inadequate to meet the needs of waiting patients, in spite of many programs and approaches to increase rates of donation. Over the years there have been numerous proposals to introduce schemes that would move toward the outright sale of organs. Three articles in this issue of the Journal propose methods for increasing organ supply—two by moving toward a market approach and the third by advocating a change in social culture. All three suffer (...)
    Direct download (6 more)  
     
    My bibliography  
     
    Export citation  
  45. Jonathan Kahn (2003). Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research. Perspectives in Biology and Medicine 46 (4):473-483.
  46. Robert E. McKeown, Douglas L. Weed, Jeffrey P. Kahn & Michael A. Stoto (2003). American College of Epidemiology Ethics Guidelines: Foundations and Dissemination. Science and Engineering Ethics 9 (2):207-214.
    Epidemiology is a core science of public health, focusing on research related to the distribution and determinants of both positive and adverse health states and events and on application of knowledge gained to improve public health. The American College of Epidemiology (ACE) is a professional organization devoted to the professional practice of epidemiology. As part of that commitment, and in response to concerns for more explicit attention to core values and duties of epidemiologists in light of emerging issues and increased (...)
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation  
  47. Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Clinical, Ethical, and Legal Issues in Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor. Journal of Law, Medicine & Ethics 31:327-39.
     
    My bibliography  
     
    Export citation  
  48. Susan M. Wolf, Jeffrey P. Kahn & John E. Wagner (2003). Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & Limits. Journal of Law, Medicine & Ethics 31 (3):327-339.
  49. Baruch Brody, Nancy Dubler, Jeff Blustein, Arthur Caplan, Jeffrey P. Kahn, Nancy Kass, Bernard Lo, Jonathan Moreno, Jeremy Sugarman & Laurie Zoloth (2002). The Task Force Responds. Hastings Center Report 32 (3):22-23.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  50. Allen E. Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John A. Robertson & Baruch A. Brody (2002). Pharmacogenetics: Ethical Issues and Policy Options. Kennedy Institute of Ethics Journal 12 (1):1-15.
    : Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians' changing responsibilities in (...)
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation  
1 — 50 / 90